Skip to main content

NCT01281527 - A 6-month, Open Label, Prospective, Multicenter, International, Exploratory Study of a Transition to Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated With Oral or Long-acting Injectable

A 6-month, Open Label, Prospective, Multicenter, International, Exploratory Study of a Transition to Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated With Oral or Long-acting Injectable Antipsychotics


Primary Citation

Not Available


Data Specification

Not Available


Annotated CRF

Available upon data request approval

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.

Product Info

Generic Name
Paliperidone palmitate
Product Name
INVEGA SUSTENNA®
Therapeutic Area
Neurosciences
Enrollment
1,044
% Female
N/A
% White
N/A
Product Class
Atypical Antipsychotics
Sponsor Protocol Number
R092670SCH3010
Data Holder
Johnson & Johnson
Condition Studied
Schizophrenia
Mean/Median Age (Years)
N/A

Supporting Documentation

Data Definition Specification Available
Annotated Case Report Form Available
Clinical Study Report
Collected Datasets
Protocol with Amendments
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.